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Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of ANCA-associated vasculitis (AAV). Clinical trials demon-
strating the efficacy of mycophenolate mofetil (MMF) for remission induction in AAV excluded patients with EGPA. Despite 
this, MMF is commonly used in these patients. The objective of this study was to evaluate, for the first time, the effectiveness 
and tolerance of MMF in EGPA remission induction. A retrospective, two-center, real-world study was conducted in patients 
with EGPA who received MMF in addition to prednisolone for newly diagnosed or relapsing disease between 2009 and 
2019. Baseline, 3-, 6- and 12-month outcome data were extracted from electronic health records. The primary outcome was 
disease remission, defined as a Birmingham Vasculitis Activity Score of 0 at 6 months. Secondary outcomes included disease 
relapse, median prednisolone dose at 12 months and drug tolerance. In total, 15 patients (73% male, median age 57) with 
EGPA (11 newly diagnosed/4 relapsing) were identified. At 6 months, 67% had achieved disease remission. At 12 months, 
this was maintained (66.7%) and 4 patients had relapsed. All but one patient remained on MMF at study completion and all 
patients tolerated MMF. Our real-world data suggest that MMF is an effective and well-tolerated agent for achieving disease 
remission in EGPA. A future randomized controlled trial of MMF in this neglected orphan disease is now warranted.
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Introduction
ANCA-associated vasculitis (AAV) includes granuloma-
tosis with polyangiitis (GPA), microscopic polyangiitis 
(MPA) and eosinophilic granulomatosis with polyangiitis 
(EGPA). ANCA seropositivity among EGPA patients is 
approximately 40%, compared to up to 90% in those with 
GPA and MPA [1]. Moreover, the pathobiology of EGPA is 
distinct, dominated by eosinophils rather than neutrophil-
based mechanisms [2]. Clinical trials in AAV have generally 
excluded those with EGPA. Consequently, the evidence base 
supporting the management of EGPA is largely inferred. The 
use of mycophenolate mofetil (MMF) in EGPA is one such 
example.
Based on expert opinion, current international clinical 
guidelines consider MMF as a therapeutic option for non-
organ threatening EGPA when used in combination with 
corticosteroids [3, 4]. MMF reduces IL-5 (the key driver of 
eosinophil maturation and function) generation in animal 
models [5] in addition to mediating inhibition of T and B 
lymphocyte proliferation [6]. A recent meta-analysis con-
cluded that MMF was an effective alternative remission-
induction agent to cyclophosphamide in AAV. Although this 
analysis excluded patients with EGPA, it did identify those 
patients with myeloperoxidase (MPO) ANCA seropositivity, 
the prevailing ANCA in EGPA, to be specifically responsive 
[7]. Despite its wide spread use, no studies have evaluated 
the efficacy and tolerance of MMF for remission induction in 
patients with EGPA. Here, we describe a real-world experi-
ence of MMF use for this indication.
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Methods
A retrospective, observational study was performed. All 
patients diagnosed with EGPA between 2009 and 2019, 
and prescribed MMF (to a target dose of 1 g twice daily as 
standard) in combination with prednisolone for remission 
induction were identified from databases of the two larg-
est regional vasculitis services in Scotland. These sites do 
not share a standardized prednisolone tapering protocol, but 
they generally follow a reduced dose taper, similar to that 
tested in the PEXIVAS trial [8], for newly diagnosed cases 
and a more modest starting dose (20–30 mg prednisolone) 
for relapsing patients. Cases were required to fulfil the 2012 
Chapel Hill Consensus definition for EGPA [9].
Data were extracted from electronic health care records. 
Baseline characteristics (Table 1) included demographics, 
duration of symptoms prior to treatment, clinical mani-
festations, serological markers and ANCA status (Indirect 
Immunofluorescence (IIF) and Enzyme Linked Immunoas-
say (ELISA). At 0, 3, 6 and 12 months, the Birmingham 
Vasculitis activity score (BVAS, version3) [10] assessed 
disease activity, and prednisolone doses were calculated. 
In addition, 1-year relapse rates (defined as the recurrence 
of symptoms and signs suggestive of EGPA requiring aug-
mentation of immunosuppression), drug in tolerance and 
infection rates were recorded.
The primary outcome was complete remission (defined as 
BVAS of 0) at 6 months. Secondary outcomes at 12 months 
were (a) complete remission, (b) partial response (a reduc-
tion of BVAS ≥ 50% compared with baseline), (c) total num-
ber of disease relapses, (d) cumulative prednisolone dose, (e) 
drug intolerance, (f) serum C-reactive protein, (g) peripheral 
eosinophil count (Table 2).
Results were reported employing summary descriptive 
statistics. As this project was a service evaluation exercise, 
the UK Health Research Authority decision tool determined 
that ethical approval was not needed (NHS Grampian R&D 
reference 5257).
Results
Of the 15 patients (11 males) identified, 11 had newly 
diagnosed EGPA and 4 had relapsing disease. At baseline 
(Table 1), median age (IQR) was 57(27–76) and 7/15 were 
MPO-ANCA positive. The remaining 8 patients were ANCA 
negative.
Lung, nerve and ENT were the most affected organs in 
our cohort. Cardiac involvement, which carries poor prog-
nosis, was evident in 2 patients.
Amongst disease relapsers (n = 4), previous immunosup-
pression included cyclophosphamide (n = 3), azathioprine 
(n = 3), methotrexate (n = 2), and rituximab (n = 1).
Ten patients (66.7%) achieved the primary outcome of 
disease remission by 6 months, and this was maintained 
at 12-month follow-up. Secondary outcomes at 12 months 
(Table 2) revealed 4 relapses. Of these, 3 had non-organ 
threatening involvement (ENT or chest flares) which 
responded to a temporary increase in prednisolone and a 
longer-term increase in MMF dose (from 2 to 3 g/day), and 
one was a relapse of peripheral neuropathy, which required a 
switch from MMF to rituximab. All other patients remained 
Table 1  Baseline characteristics (n = 15)
a Pulmonary infiltrate /nodularity was found in 9 patients(60%)
b Individual BVAS is provided in supplementary table
Demography
Sex M/F 11/4
Age, median (IQR) 57 (27–76)
Characteristics at EGPA diagnosis
Organ involvement (%)





 Cardiac involvement 2 (13%)
 Renal 1 (7%)
 Median eosinophil  109/l (IQR) 3.48 (0.01–21)
 Positive ANCA 7 (47%)
 BVAS, median (IQR)b 11 (4–24)
Table 2  Primary and secondary 
outcomes
Baseline 6 months 12 months
Complete remission NA 10/15 (67%) 10/15 (67%)
Partial response NA 3/15 (20%) 4/15 (27%)
Median cumulative prednisolone dose NA 3.1 g (1–5.7) 4.7 g (1.9–7.9)
Total relapses NA 2/15 (13%) 4/15 (27%)
Drug intolerance NA Nil reported Nil reported
Median eosinophils count ×  109/l (IQR) 3.48 (0.01–21) 0.2 (0.02–1) 0.16 (0.01–0.65)
Median CRP mg/L (IQR) 13.5 (< 4–113)  < 4 (1–12)  < 4 (< 4–120)
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on 2 g/day MMF at 1 year. No patients were intolerant of 
MMF. Specifically, no allergic reactions were observed 
nor was gastrointestinal disturbance reported. Six patients 
experienced infections (5 respiratory, 1 urinary), one which 
was considered severe. All patients with baseline peripheral 
blood eosinophilia, recorded a normal eosinophil count at 
6 and 12 months. Median prednisolone doses were 7.5 and 
5 mg/day at 6 and 12 months, while the cumulative predni-
solone doses were 3.1 and 4.7 g, respectively. The predniso-
lone dose was increased 7 times in 7 patients.
Outcomes of newly diagnosed EGPA patients were 
broadly comparable to those with disease relapse, as were 
outcomes stratified by ANCA status where the complete 
remission for the positive group was achieved in 71% and 
63% in the ANCA negative group (Supplementary Tables 1 
and 2).
Discussion
In this retrospective evaluation, almost all newly diagnosed 
and relapsing EGPA patients responded to MMF in combi-
nation with prednisolone; two-thirds successfully achieving 
disease remission at 6 months. Moreover, after 1 year of 
follow-up, all patients tolerated MMF and only one patient 
switched immunosuppression.
This is the first study to examine the role of MMF in 
EGPA. In fact, very few studies have evaluated any therapy 
in EGPA and only mepolizumab has been tested by a ran-
domized controlled trial. Compared to placebo, this IL-5 
blocker demonstrated superior efficacy with approximately 
a third of patients achieving complete remission at 1 year. 
Although significantly less than the 67% remission rate 
reported in this study, the trial of mepolizumab selectively 
recruited relapsing or refractory EGPA patients, by defini-
tion a more treatment resistant population [11]. In keep-
ing with this, the remission rate for those newly diagnosed 
(n = 11) in our study was even higher 82% and 73% at 6 and 
12 months, respectively) and for the relapse group (n = 4) 
the remission rate was 25% and 50% at 6 and 12 months, 
respectively.
Another retrospective observational study, which exam-
ined the role of rituximab in EGPA [12], comprised of 
patients with similar baseline levels of disease activity to 
our study, but again included mostly relapsing/refractory 
patients. This, again, likely explains the apparent lower 
remission rates (34% vs. 67% at 6 months and 49% vs. 
67% at 12 months) and steroid sparing effects (53% vs. 
67% < 10 mg prednisolone at 12 months) between RTX 
and MMF. The median cumulative prednisolone exposure 
in this study (4.7 g at 12 months) is largely similar to what 
was observed in an open label prospective EGPA study of 
methotrexate and much less than older cohorts which often 
did not use corticosteroid-sparing agents [13].
In comparison to other AAV subtypes, our data are 
remarkably similar to the outcomes of the MYCYC trial. 
In this randomized controlled trial of MMF versus cyclo-
phosphamide for GPA/MPA remission induction, subjects 
randomized to MMF achieved complete remission rates of 
67% at 6 months and relapse rates of 25% at 1 year [14]. 
In other cohorts, relapse rates of 50% at 21 months [13] 
and 44% at 24 months [15] have been reported, which 
compares to the 27% at 12 months observed in this study.
Key study limitations should be considered. First, this is 
a small sample size subject to selection bias and confound-
ing. MMF is not the only first-line remission-induction 
agent used by the contributing vasculitis services and the 
ultimate therapeutic choice was determined by individual 
patient factors. Generally, MMF is used for non-organ 
threatening presentations, although in this cohort, n = 10 
and n = 2 manifested neuropathic and cardiac involvement, 
respectively. Second, this study is retrospective in design. 
The centralization of our electronic health records helped 
optimize data capture but the possibility of measurement 
error when computing granular outcomes, such as cumula-
tive prednisolone dose and measuring BVAS score, cannot 
be excluded. Third, without a placebo comparison group, it 
is not possible to attribute the observed outcome improve-
ments to MMF alone. Contextualization with historical 
cohorts is helpful but direct comparisons are imperfect 
since many of the outcomes are not identically defined. A 
randomized controlled trial is essential to determine true 
efficacy. Fourth, 1-year follow-up of subjects is adequate 
to evaluate remission induction but insufficient to evaluate 
remission maintenance.
In summary, MMF appears to be well tolerated and 
effective for inducing disease remission among patients 
with newly diagnosed or relapsing EGPA. Despite differ-
ences with GPA/MPA, these data are the first to support 
existing expert-based guidelines which recommend MMF 
as a useful remission induction option across the spectrum 
of AAV. Although reassuring, this is a small observational 
study vulnerable to confounding. Well-designed rand-
omized controlled trials are imperative to full ascertain 
the role of this drug in this frequently neglected burden-
some condition.
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